Literature DB >> 3801954

Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum.

E G MacEwen, A K Patnaik, H J Harvey, A A Hayes, R Matus.   

Abstract

Eighty-nine dogs with malignant oral melanoma were selected for study. All dogs were clinically staged and treated with either surgical excision alone or surgery plus C. parvum immunotherapy. There was no difference in survival time between the two treatment groups. However, in dogs with advanced disease (Stages II, III) there was a statistical difference between surgery alone versus surgery plus C. parvum (p = 0.01). Dogs with Stage I disease (tumor less than 2 cm diameter) had a statistically improved survival (p = 0.02) regardless of the therapy given. These results suggest that C. parvum, when combined with surgery, may have antitumor activity in the canine melanoma model.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3801954     DOI: 10.3109/07357908609017520

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  25 in total

1.  Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.

Authors:  Jack C F Liao; Polly Gregor; Jedd D Wolchok; Francesca Orlandi; Diane Craft; Carrie Leung; Alan N Houghton; Philip J Bergman
Journal:  Cancer Immun       Date:  2006-04-21

2.  Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.

Authors:  Suzanne Shelly; May B Chien; Becky Yip; Michael S Kent; Alain P Theon; Jennifer L McCallan; Cheryl A London
Journal:  Mamm Genome       Date:  2005-03       Impact factor: 2.957

3.  6-Bromoindirubin-3'oxime (BIO) decreases proliferation and migration of canine melanoma cell lines.

Authors:  Esther Chon; Brandi Flanagan; Lucas Campos de Sá Rodrigues; Caroline Piskun; Timothy J Stein
Journal:  Vet J       Date:  2014-07-31       Impact factor: 2.688

Review 4.  Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment.

Authors:  E G MacEwen
Journal:  Cancer Metastasis Rev       Date:  1990-09       Impact factor: 9.264

5.  Clinical systemic lupeol administration for canine oral malignant melanoma.

Authors:  Inoru Yokoe; Kazuo Azuma; Keishi Hata; Toshiyuki Mukaiyama; Takahiro Goto; Takeshi Tsuka; Tomohiro Imagawa; Norihiko Itoh; Yusuke Murahata; Tomohiro Osaki; Saburo Minami; Yoshiharu Okamoto
Journal:  Mol Clin Oncol       Date:  2014-10-30

6.  Activation of the canonical Wnt/β-catenin signalling pathway is rare in canine malignant melanoma tissue and cell lines.

Authors:  E Chon; V Thompson; S Schmid; T J Stein
Journal:  J Comp Pathol       Date:  2012-08-14       Impact factor: 1.311

7.  In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma.

Authors:  S W Dow; R E Elmslie; A P Willson; L Roche; C Gorman; T A Potter
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

8.  Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs.

Authors:  S C Helfand; S A Soergel; P S MacWilliams; J A Hank; P M Sondel
Journal:  Cancer Immunol Immunother       Date:  1994-08       Impact factor: 6.968

9.  Pevonedistat targeted therapy inhibits canine melanoma cell growth through induction of DNA re-replication and senescence.

Authors:  Elizabeth A Wood; Zhanping Lu; Shuai Jia; Anna L F V Assumpção; Matthew A Van Hesteren; Mike K Huelsmeyer; David M Vail; Xuan Pan
Journal:  Vet Comp Oncol       Date:  2019-10-30       Impact factor: 2.613

Review 10.  DNA vaccines in veterinary use.

Authors:  Laurel Redding; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.